Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients

R J Creger; R I Cowan; H S Nearman; J L Blumer; W R Selman; L H Danziger

doi:10.1128/AAC.28.6.839

Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients

R J Creger
, R I Cowan
, H S Nearman
, J L Blumer
, W R Selman
, L H Danziger

Research output: Contribution to journal › Article › peer-review

Abstract

The cerebrospinal fluid penetration of moxalactam was simultaneously investigated in three patients with presumed bacterial meningitis. When ratios of simultaneously drawn ventriculostomy to serum moxalactam levels of 1, 2, 3, and 4 h were examined, the penetration ratios were 7.8 +/- 2.4, 11.2 +/- 1.3, 14.2 +/- 2.5, and 15.0 +/- 4.9%, respectively. These ratios were not statistically different from the penetration of moxalactam calculated by the area under the concentration-time curve technique (8.97 +/- 1.89%).

Original language	English
Pages (from-to)	839-41
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	28
Issue number	6
DOIs	https://doi.org/10.1128/AAC.28.6.839
State	Published - Dec 1985

Keywords

Drug Administration Schedule
Humans
Kinetics
Meningitis/drug therapy
Metabolic Clearance Rate
Moxalactam/blood
Time Factors

Access to Document

10.1128/AAC.28.6.839

Cite this

@article{8553c8cd3e954725a58bb2503e50f311,

title = "Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients",

abstract = "The cerebrospinal fluid penetration of moxalactam was simultaneously investigated in three patients with presumed bacterial meningitis. When ratios of simultaneously drawn ventriculostomy to serum moxalactam levels of 1, 2, 3, and 4 h were examined, the penetration ratios were 7.8 +/- 2.4, 11.2 +/- 1.3, 14.2 +/- 2.5, and 15.0 +/- 4.9\%, respectively. These ratios were not statistically different from the penetration of moxalactam calculated by the area under the concentration-time curve technique (8.97 +/- 1.89\%).",

keywords = "Drug Administration Schedule, Humans, Kinetics, Meningitis/drug therapy, Metabolic Clearance Rate, Moxalactam/blood, Time Factors",

author = "Creger, \{R J\} and Cowan, \{R I\} and Nearman, \{H S\} and Blumer, \{J L\} and Selman, \{W R\} and Danziger, \{L H\}",

year = "1985",

month = dec,

doi = "10.1128/AAC.28.6.839",

language = "English",

volume = "28",

pages = "839--41",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

number = "6",

}

TY - JOUR

T1 - Cerebrospinal fluid penetration of moxalactam in ventriculostomy patients

AU - Creger, R J

AU - Cowan, R I

AU - Nearman, H S

AU - Blumer, J L

AU - Selman, W R

AU - Danziger, L H

PY - 1985/12

Y1 - 1985/12

N2 - The cerebrospinal fluid penetration of moxalactam was simultaneously investigated in three patients with presumed bacterial meningitis. When ratios of simultaneously drawn ventriculostomy to serum moxalactam levels of 1, 2, 3, and 4 h were examined, the penetration ratios were 7.8 +/- 2.4, 11.2 +/- 1.3, 14.2 +/- 2.5, and 15.0 +/- 4.9%, respectively. These ratios were not statistically different from the penetration of moxalactam calculated by the area under the concentration-time curve technique (8.97 +/- 1.89%).

AB - The cerebrospinal fluid penetration of moxalactam was simultaneously investigated in three patients with presumed bacterial meningitis. When ratios of simultaneously drawn ventriculostomy to serum moxalactam levels of 1, 2, 3, and 4 h were examined, the penetration ratios were 7.8 +/- 2.4, 11.2 +/- 1.3, 14.2 +/- 2.5, and 15.0 +/- 4.9%, respectively. These ratios were not statistically different from the penetration of moxalactam calculated by the area under the concentration-time curve technique (8.97 +/- 1.89%).

KW - Drug Administration Schedule

KW - Humans

KW - Kinetics

KW - Meningitis/drug therapy

KW - Metabolic Clearance Rate

KW - Moxalactam/blood

KW - Time Factors

U2 - 10.1128/AAC.28.6.839

DO - 10.1128/AAC.28.6.839

M3 - Article

C2 - 4083867

SN - 0066-4804

VL - 28

SP - 839

EP - 841

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 6

ER -